Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Raw Materials (2016 - 2025)

Avanos Medical (AVNS) has disclosed Raw Materials for 12 consecutive years, with $4.1 million as the latest value for Q4 2025.

  • Quarterly Raw Materials rose 41.38% to $4.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.1 million through Dec 2025, up 41.38% year-over-year, with the annual reading at $4.1 million for FY2025, 41.38% up from the prior year.
  • Raw Materials hit $4.1 million in Q4 2025 for Avanos Medical, up from $4.0 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $57.0 million in Q1 2023 to a low of $2.9 million in Q4 2024.
  • Historically, Raw Materials has averaged $31.5 million across 5 years, with a median of $39.2 million in 2023.
  • Biggest YoY gain for Raw Materials was 841.03% in 2025; the steepest drop was 91.56% in 2025.
  • Year by year, Raw Materials stood at $6.8 million in 2021, then surged by 439.71% to $36.7 million in 2022, then plummeted by 87.47% to $4.6 million in 2023, then crashed by 36.96% to $2.9 million in 2024, then surged by 41.38% to $4.1 million in 2025.
  • Business Quant data shows Raw Materials for AVNS at $4.1 million in Q4 2025, $4.0 million in Q3 2025, and $36.7 million in Q2 2025.